$AMRX
Amneal Pharmaceuticals, Inc. Stock $amrx

$amrx Overview Financials Valuation SEC Filings Company Website

2022 Q2 Form 10-Q Financial Statement

#000172312822000034 Filed on August 08, 2022

Income Statement

Concept	2022 Q2	2021 Q4	2021 Q2
Revenue	$559.4M	$536.9M	$535.1M
YoY Change	4.54%	5.27%	15.15%
Cost Of Revenue	$353.7M	$348.5M	$322.6M
YoY Change	9.66%	1.6%	0.91%
Gross Profit	$200.5M	$188.4M	$212.5M
YoY Change	-5.64%	12.75%	47.33%
Gross Profit Margin	35.85%	35.09%	39.71%
Selling, General & Admin	$98.81M	$98.37M	$86.16M
YoY Change	14.68%	11.27%	6.44%
% of Gross Profit	49.28%	52.21%	40.54%
Research & Development	$50.75M	$51.87M	$52.86M
YoY Change	-4.0%	-3.04%	16.0%
% of Gross Profit	25.31%	27.53%	24.88%
Depreciation & Amortization	$59.70M	$61.18M	$56.54M
YoY Change	5.59%	2.14%	-2.69%
% of Gross Profit	29.77%	32.47%	26.61%
Operating Expenses	$149.6M	$150.1M	$139.0M
YoY Change	7.58%	5.81%	9.88%
Operating Profit	-$198.6M	$38.27M	$67.12M
YoY Change	-395.92%	51.85%	524.3%
Interest Expense	-$35.62M	-$34.13M	-$34.08M
YoY Change	4.52%	30.75%	-7.05%
% of Operating Profit		-89.18%	-50.78%
Other Income/Expense, Net	-$34.11M	$6.633M	-$32.30M
YoY Change	5.63%	1226.6%	-0.66%
Pretax Income	-$232.7M	-$16.32M	$34.82M
YoY Change	-768.31%	196.71%	-260.05%
Income Tax	$7.400M	$4.140M	$2.600M
% Of Pretax Income			7.47%
Net Earnings	-$242.1M	-$6.377M	$29.99M
YoY Change	-907.28%	112.57%	-224.12%
Net Earnings / Revenue	-43.29%	-1.19%	5.61%
Basic Earnings Per Share	-$0.80		$0.10
Diluted Earnings Per Share	-$0.80	-$42.69K	$0.10
COMMON SHARES
Basic Shares Outstanding	151.0M shares		149.0M shares
Diluted Shares Outstanding	151.0M shares		152.0M shares

Balance Sheet

Concept	2022 Q2	2021 Q4	2021 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$91.98M	$247.8M	$278.3M
YoY Change	-66.95%	-27.42%	4.59%
Cash & Equivalents	$91.98M	$247.8M	$278.3M
Short-Term Investments
Other Short-Term Assets	$202.0M	$55.19M	$43.52M
YoY Change	364.15%	21.83%	-12.96%
Inventory	$533.0M	$489.4M	$523.4M
Prepaid Expenses
Receivables	$688.8M	$662.6M	$652.0M
Other Receivables	$17.75M	$9.770M	$43.88M
Total Short-Term Assets	$1.554B	$1.520B	$1.563B
YoY Change	-0.63%	-2.03%	5.58%
LONG-TERM ASSETS
Property, Plant & Equipment	$483.6M	$514.2M	$468.4M
YoY Change	3.25%	7.62%	1.71%
Goodwill	$601.0M	$593.0M	$549.1M
YoY Change	9.45%	13.43%	4.1%
Intangibles	$1.204B	$1.167B	$1.293B
YoY Change	-6.89%	-10.56%	-9.17%
Long-Term Investments
YoY Change
Other Assets	$79.84M	$20.61M	$19.22M
YoY Change	315.47%	-7.74%	-33.12%
Total Long-Term Assets	$2.488B	$2.420B	$2.460B
YoY Change	1.15%	-1.42%	-4.52%
TOTAL ASSETS
Total Short-Term Assets	$1.554B	$1.520B	$1.563B
Total Long-Term Assets	$2.488B	$2.420B	$2.460B
Total Assets	$4.041B	$3.940B	$4.023B
YoY Change	0.46%	-1.66%	-0.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$561.7M	$131.1M	$596.2M
YoY Change	-5.79%	-14.4%	-0.55%
Accrued Expenses	$12.89M	$12.32M	$10.44M
YoY Change	23.51%	32.49%	-35.96%
Deferred Revenue
YoY Change
Short-Term Debt	$85.00M	$0.00	$0.00
YoY Change
Long-Term Debt Due	$29.92M	$30.61M	$30.46M
YoY Change	-1.78%	-30.78%	2.37%
Total Short-Term Liabilities	$993.1M	$677.2M	$672.9M
YoY Change	47.59%	0.05%	2.72%
LONG-TERM LIABILITIES
Long-Term Debt	$2.622B	$2.680B	$2.720B
YoY Change	-3.59%	-2.02%	-1.61%
Other Long-Term Liabilities	$79.21M	$38.90M	$63.26M
YoY Change	25.23%	-53.33%	-32.54%
Total Long-Term Liabilities	$2.857B	$2.879B	$2.946B
YoY Change	-3.0%	-3.16%	-2.4%
TOTAL LIABILITIES
Total Short-Term Liabilities	$993.1M	$677.2M	$672.9M
Total Long-Term Liabilities	$2.857B	$2.879B	$2.946B
Total Liabilities	$3.851B	$3.556B	$3.619B
YoY Change	6.41%	-2.56%	-1.49%
SHAREHOLDERS EQUITY
Retained Earnings	-$399.2M	-$276.2M	-$265.6M
YoY Change	50.3%	-3.7%	-3.36%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$280.3M	$360.3M	$346.1M
YoY Change
Total Liabilities & Shareholders Equity	$4.041B	$3.940B	$4.023B
YoY Change	0.46%	-1.66%	-0.83%

Cashflow Statement

Concept	2022 Q2	2021 Q4	2021 Q2
OPERATING ACTIVITIES
Net Income	-$242.1M	-$6.377M	$29.99M
YoY Change	-907.28%	112.57%	-224.12%
Depreciation, Depletion And Amortization	$59.70M	$61.18M	$56.54M
YoY Change	5.59%	2.14%	-2.69%
Cash From Operating Activities	-$125.5M	$63.26M	-$51.91M
YoY Change	141.83%	-40.32%	-128.95%
INVESTING ACTIVITIES
Capital Expenditures	-$17.12M	-$19.25M	-$9.052M
YoY Change	89.09%	-39.45%	5.26%
Acquisitions
YoY Change
Other Investing Activities	$1.000M	-$67.72M	-$73.83M
YoY Change	-101.35%		18357.0%
Cash From Investing Activities	-$16.12M	-$86.97M	-$82.88M
YoY Change	-80.56%	174.35%	820.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	23.25M	-30.35M	-38.12M
YoY Change	-160.99%	168.58%	-87.71%
NET CHANGE
Cash From Operating Activities	-125.5M	63.26M	-51.91M
Cash From Investing Activities	-16.12M	-86.97M	-82.88M
Cash From Financing Activities	23.25M	-30.35M	-38.12M
Net Change In Cash	-118.4M	-54.06M	-172.9M
YoY Change	-31.53%	-185.81%	23.68%
FREE CASH FLOW
Cash From Operating Activities	-$125.5M	$63.26M	-$51.91M
Capital Expenditures	-$17.12M	-$19.25M	-$9.052M
Free Cash Flow	-$108.4M	$82.52M	-$42.85M
YoY Change	152.97%	-40.12%	-122.81%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001723128
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Type DocumentType	10-Q
	dei	Entity Registrant Name EntityRegistrantName	Amneal Pharmaceuticals, Inc.
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity File Number EntityFileNumber	001-38485
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	32-0546926
	dei	Entity Address Address Line1 EntityAddressAddressLine1	400 Crossing Boulevard,
	dei	Entity Address City Or Town EntityAddressCityOrTown	Bridgewater
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	08807
	dei	City Area Code CityAreaCode	908
	dei	Local Phone Number LocalPhoneNumber	947-3120
	dei	Security12b Title Security12bTitle	Class A Common Stock, par value $0.01 per share
	dei	Trading Symbol TradingSymbol	AMRX
	dei	Security Exchange Name SecurityExchangeName	NYSE
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	559355000	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	535075000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1056988000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1028180000	usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	353724000	usd
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	322577000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	676786000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	624120000	usd
CY2022Q2	amrx	Cost Of Goods And Services Sold Impairment Charges CostOfGoodsAndServicesSoldImpairmentCharges	5112000	usd
CY2021Q2	amrx	Cost Of Goods And Services Sold Impairment Charges CostOfGoodsAndServicesSoldImpairmentCharges	0	usd
	amrx	Cost Of Goods And Services Sold Impairment Charges CostOfGoodsAndServicesSoldImpairmentCharges	5112000	usd
	amrx	Cost Of Goods And Services Sold Impairment Charges CostOfGoodsAndServicesSoldImpairmentCharges	0	usd
	us-gaap	Gross Profit GrossProfit	404060000	usd
CY2022Q2	us-gaap	Restructuring Charges RestructuringCharges	0	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	200519000	usd
CY2021Q2	us-gaap	Gross Profit GrossProfit	212498000	usd
	us-gaap	Gross Profit GrossProfit	375090000	usd
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	98806000	usd
CY2021Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	86157000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	197471000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	176883000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	50748000	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	52864000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	103546000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	101046000	usd
CY2022Q2	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2021Q2	us-gaap	Asset Impairment Charges AssetImpairmentCharges	710000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	710000	usd
CY2022Q2	us-gaap	Royalty Expense RoyaltyExpense	821000	usd
CY2021Q2	us-gaap	Royalty Expense RoyaltyExpense	1365000	usd
	us-gaap	Royalty Expense RoyaltyExpense	1585000	usd
	us-gaap	Royalty Expense RoyaltyExpense	4947000	usd
CY2022Q2	amrx	Business Combination Acquisition Related Costs Transaction Related And Integration Expense BusinessCombinationAcquisitionRelatedCostsTransactionRelatedAndIntegrationExpense	241000	usd
CY2021Q2	amrx	Business Combination Acquisition Related Costs Transaction Related And Integration Expense BusinessCombinationAcquisitionRelatedCostsTransactionRelatedAndIntegrationExpense	4283000	usd
	amrx	Business Combination Acquisition Related Costs Transaction Related And Integration Expense BusinessCombinationAcquisitionRelatedCostsTransactionRelatedAndIntegrationExpense	675000	usd
	amrx	Business Combination Acquisition Related Costs Transaction Related And Integration Expense BusinessCombinationAcquisitionRelatedCostsTransactionRelatedAndIntegrationExpense	7085000	usd
CY2022Q2	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-251877000	usd
CY2021Q2	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	usd
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-249551000	usd
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	usd
CY2022Q2	us-gaap	Insurance Recoveries InsuranceRecoveries	1911000	usd
CY2021Q2	us-gaap	Insurance Recoveries InsuranceRecoveries	0	usd
	us-gaap	Insurance Recoveries InsuranceRecoveries	1911000	usd
	us-gaap	Insurance Recoveries InsuranceRecoveries	0	usd
CY2021Q2	us-gaap	Restructuring Charges RestructuringCharges	0	usd
	us-gaap	Restructuring Charges RestructuringCharges	731000	usd
	us-gaap	Restructuring Charges RestructuringCharges	363000	usd
CY2022Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-270000	usd
CY2021Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-70000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	usd
CY2022Q2	amrx	Other Income Operating OtherIncomeOperating	1175000	usd
CY2021Q2	amrx	Other Income Operating OtherIncomeOperating	0	usd
	amrx	Other Income Operating OtherIncomeOperating	1175000	usd
	amrx	Other Income Operating OtherIncomeOperating	0	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-198618000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	67119000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-175313000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	113026000	usd
CY2022Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-35623000	usd
CY2021Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-34083000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-68958000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-67968000	usd
CY2022Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-5429000	usd
CY2021Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-2244000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-7442000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-156000	usd
CY2022Q2	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt	-291000	usd
CY2021Q2	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt	0	usd
	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt	-291000	usd
	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt	0	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	7230000	usd
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4032000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	9352000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4826000	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-34113000	usd
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-32295000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-67339000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-63298000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-232731000	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	34824000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-242652000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	49728000	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7350000	usd
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2648000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3889000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3007000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-240081000	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	32176000	usd
	us-gaap	Profit Loss ProfitLoss	-246541000	usd
	us-gaap	Profit Loss ProfitLoss	46721000	usd
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-119273000	usd
CY2021Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	17644000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-124015000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	25483000	usd
CY2022Q2	amrx	Net Income Loss Attributable To Parent Before Accretion Of Redeemable Noncontrolling Interest NetIncomeLossAttributableToParentBeforeAccretionOfRedeemableNoncontrollingInterest	-120808000	usd
CY2021Q2	amrx	Net Income Loss Attributable To Parent Before Accretion Of Redeemable Noncontrolling Interest NetIncomeLossAttributableToParentBeforeAccretionOfRedeemableNoncontrollingInterest	14532000	usd
	amrx	Net Income Loss Attributable To Parent Before Accretion Of Redeemable Noncontrolling Interest NetIncomeLossAttributableToParentBeforeAccretionOfRedeemableNoncontrollingInterest	-122526000	usd
	amrx	Net Income Loss Attributable To Parent Before Accretion Of Redeemable Noncontrolling Interest NetIncomeLossAttributableToParentBeforeAccretionOfRedeemableNoncontrollingInterest	21238000	usd
CY2022Q2	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	usd
CY2021Q2	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	usd
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	438000	usd
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-120808000	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	14532000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-122964000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	21238000	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.80
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.10
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.82
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.14
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.80
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.10
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.82
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.14
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	150993000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	148996000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	150445000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	148507000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	150993000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	151986000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	150445000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	151606000	shares
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-240081000	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	32176000	usd
	us-gaap	Profit Loss ProfitLoss	-246541000	usd
	us-gaap	Profit Loss ProfitLoss	46721000	usd
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-119273000	usd
CY2021Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	17644000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-124015000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	25483000	usd
CY2022Q2	amrx	Net Income Loss Attributable To Parent Before Accretion Of Redeemable Noncontrolling Interest NetIncomeLossAttributableToParentBeforeAccretionOfRedeemableNoncontrollingInterest	-120808000	usd
CY2021Q2	amrx	Net Income Loss Attributable To Parent Before Accretion Of Redeemable Noncontrolling Interest NetIncomeLossAttributableToParentBeforeAccretionOfRedeemableNoncontrollingInterest	14532000	usd
	amrx	Net Income Loss Attributable To Parent Before Accretion Of Redeemable Noncontrolling Interest NetIncomeLossAttributableToParentBeforeAccretionOfRedeemableNoncontrollingInterest	-122526000	usd
	amrx	Net Income Loss Attributable To Parent Before Accretion Of Redeemable Noncontrolling Interest NetIncomeLossAttributableToParentBeforeAccretionOfRedeemableNoncontrollingInterest	21238000	usd
CY2022Q2	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	usd
CY2021Q2	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	usd
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	438000	usd
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-120808000	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	14532000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-122964000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	21238000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-11628000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	182000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-15707000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-6184000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	14070000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	704000	usd
	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	67694000	usd
	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	21476000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	1225000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	448000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	26180000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	7750000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1217000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	438000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	25807000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	7542000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-119591000	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	14970000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-97157000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	28780000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	91979000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	247790000	usd
CY2022Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	6203000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	8949000	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	688849000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	662583000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	533028000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	489389000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	232204000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	110218000	usd
CY2022Q2	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	1338000	usd
CY2021Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	1179000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	1553601000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	1520108000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	483625000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	514158000	usd
CY2022Q2	us-gaap	Goodwill Goodwill	600974000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	593017000	usd
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1204224000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1166922000	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	79836000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	20614000	usd
CY2022Q2	us-gaap	Assets Assets	4041405000	usd
CY2021Q4	us-gaap	Assets Assets	3939664000	usd
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	561692000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	525345000	usd
CY2022Q2	us-gaap	Litigation Reserve Current LitigationReserveCurrent	275338000	usd
CY2021Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	58000000	usd
CY2022Q2	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	85000000	usd
CY2021Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	0	usd
CY2022Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	29920000	usd
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	30614000	usd
CY2022Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	24904000	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	47861000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	993064000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	677243000	usd
CY2022Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2622447000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2680053000	usd
CY2022Q2	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	38856000	usd
CY2021Q4	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	38038000	usd
CY2022Q2	us-gaap	Due To Affiliate Noncurrent DueToAffiliateNoncurrent	10654000	usd
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	79213000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	38903000	usd
CY2022Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2857465000	usd
CY2021Q4	us-gaap	Due To Affiliate Noncurrent DueToAffiliateNoncurrent	9619000	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2878541000	usd
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q2	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	17885000	usd
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	16907000	usd
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	675588000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	658350000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-399161000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-276197000	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	868000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-24827000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	280327000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	360340000	usd
CY2022Q2	us-gaap	Minority Interest MinorityInterest	-107336000	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	6633000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	172991000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	366973000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4041405000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3939664000	usd
	us-gaap	Profit Loss ProfitLoss	-246541000	usd
	us-gaap	Profit Loss ProfitLoss	46721000	usd
	amrx	Depreciation Depletion And Amortization Excluding Amortization Of Debt Issuance Costs DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts	117511000	usd
	amrx	Depreciation Depletion And Amortization Excluding Amortization Of Debt Issuance Costs DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts	112037000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-2764000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-8014000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-124000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	4388000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	4473000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-291000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	5112000	usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	710000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	1000000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	0	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	16327000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	12962000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	17748000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	25805000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-70000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-3449000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	26561000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	13167000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	65395000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	54580000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	119747000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	23988000	usd
	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	159000	usd
	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	-7383000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	273947000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-21137000	usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	7508000	usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-3912000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5178000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	96195000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	15842000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	19585000	usd
	amrx	Payments To Acquire Property Plant And Equipment Deposits PaymentsToAcquirePropertyPlantAndEquipmentDeposits	3955000	usd
	amrx	Payments To Acquire Property Plant And Equipment Deposits PaymentsToAcquirePropertyPlantAndEquipmentDeposits	1667000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	10000000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	500000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	84714000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	73828000	usd
	us-gaap	Proceeds From Life Insurance Policies ProceedsFromLifeInsurancePolicies	1000000	usd
	us-gaap	Proceeds From Life Insurance Policies ProceedsFromLifeInsurancePolicies	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-113511000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-95580000	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	1622000	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	usd
	amrx	Repayments Of Long Term Debt And Financing Lease Obligations RepaymentsOfLongTermDebtAndFinancingLeaseObligations	63010000	usd
	amrx	Repayments Of Long Term Debt And Financing Lease Obligations RepaymentsOfLongTermDebtAndFinancingLeaseObligations	33876000	usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	85000000	usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	239000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	681000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	3291000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2378000	usd
	amrx	Tax Distribution To Noncontrolling Interest Financing Activities TaxDistributionToNoncontrollingInterestFinancingActivities	9917000	usd
	amrx	Tax Distribution To Noncontrolling Interest Financing Activities TaxDistributionToNoncontrollingInterestFinancingActivities	27551000	usd
	us-gaap	Payments For Repurchase Of Redeemable Noncontrolling Interest PaymentsForRepurchaseOfRedeemableNoncontrollingInterest	1722000	usd
	us-gaap	Payments For Repurchase Of Redeemable Noncontrolling Interest PaymentsForRepurchaseOfRedeemableNoncontrollingInterest	0	usd
	amrx	Payment Of Deferred Consideration For Acquisition Related Party PaymentOfDeferredConsiderationForAcquisitionRelatedParty	43998000	usd
	amrx	Payment Of Deferred Consideration For Acquisition Related Party PaymentOfDeferredConsiderationForAcquisitionRelatedParty	0	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	93000	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	1000000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-38321000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-64217000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1547000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-366000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-158557000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-63968000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	256739000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	347121000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	98182000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	283153000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	91979000	usd
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	278306000	usd
CY2022Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	6203000	usd
CY2021Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	4847000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	98182000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	283153000	usd
	us-gaap	Interest Paid Net InterestPaidNet	57322000	usd
	us-gaap	Interest Paid Net InterestPaidNet	61441000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-6747000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	4610000	usd
	amrx	Noncash Or Part Noncash Acquisition Contingent Consideration For Acquisition NoncashOrPartNoncashAcquisitionContingentConsiderationForAcquisition	8796000	usd
	amrx	Noncash Or Part Noncash Acquisition Contingent Consideration For Acquisition NoncashOrPartNoncashAcquisitionContingentConsiderationForAcquisition	0	usd
	amrx	Intangible Asset Expenditures Incurred But Not Yet Paid IntangibleAssetExpendituresIncurredButNotYetPaid	31500000	usd
	amrx	Intangible Asset Expenditures Incurred But Not Yet Paid IntangibleAssetExpendituresIncurredButNotYetPaid	0	usd
	amrx	Noncash Or Part Noncash Acquisition Deferred Consideration For Acquisition Related Party NoncashOrPartNoncashAcquisitionDeferredConsiderationForAcquisitionRelatedParty	0	usd
	amrx	Noncash Or Part Noncash Acquisition Deferred Consideration For Acquisition Related Party NoncashOrPartNoncashAcquisitionDeferredConsiderationForAcquisitionRelatedParty	30099000	usd
	amrx	Noncash Or Part Noncash Acquisition Contingent Consideration For Acquisition Related Party NoncashOrPartNoncashAcquisitionContingentConsiderationForAcquisitionRelatedParty	0	usd
	amrx	Noncash Or Part Noncash Acquisition Contingent Consideration For Acquisition Related Party NoncashOrPartNoncashAcquisitionContingentConsiderationForAcquisitionRelatedParty	6100000	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	407407000	usd
CY2022Q1	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	16420000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-242128000	usd
CY2022Q2	us-gaap	Temporary Equity Net Income TemporaryEquityNetIncome	2047000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-11628000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8262000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	128000	usd
CY2022Q2	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-233000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	14070000	usd
CY2022Q2	amrx	Temporary Equity Tax Distribution TemporaryEquityTaxDistribution	582000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	172991000	usd
CY2022Q2	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	17885000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	366973000	usd
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	16907000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-250945000	usd
	us-gaap	Temporary Equity Net Income TemporaryEquityNetIncome	4404000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-15707000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	16327000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	239000	usd
	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-3377000	usd
	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	67694000	usd
	amrx	Temporary Equity Tax Distribution TemporaryEquityTaxDistribution	2587000	usd
	us-gaap	Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock	883000	usd
	amrx	Temporary Equity Reclassification Of Redeemable Non Controlling Interest TemporaryEquityReclassificationOfRedeemableNonControllingInterest	883000	usd
	amrx	Temporary Equity Acquisition Of Redeemable Non Controlling Interest TemporaryEquityAcquisitionOfRedeemableNonControllingInterest	1722000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	172991000	usd
CY2022Q2	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	17885000	usd
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	366708000	usd
CY2021Q1	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	13079000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	29993000	usd
CY2021Q2	us-gaap	Temporary Equity Net Income TemporaryEquityNetIncome	2183000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	182000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7632000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5000	usd
CY2021Q2	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-308000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	704000	usd
CY2021Q2	amrx	Temporary Equity Tax Distribution TemporaryEquityTaxDistribution	1150000	usd
CY2021Q2	us-gaap	Noncontrolling Interest Increase From Business Combination NoncontrollingInterestIncreaseFromBusinessCombination	2000000	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	390272000	usd
CY2021Q2	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	14112000	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	344932000	usd
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	11804000	usd
	us-gaap	Net Income Loss NetIncomeLoss	42742000	usd
	us-gaap	Temporary Equity Net Income TemporaryEquityNetIncome	3979000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-6184000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12962000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	681000	usd
	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-2457000	usd
	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	21476000	usd
	amrx	Temporary Equity Tax Distribution TemporaryEquityTaxDistribution	1671000	usd
	us-gaap	Noncontrolling Interest Increase From Business Combination NoncontrollingInterestIncreaseFromBusinessCombination	2000000	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	390272000	usd
CY2021Q2	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	14112000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:106%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements requires the Company's management to make estimates and assumptions that affect the reported financial position at the date of the financial statements and the reported results of operations during the reporting period. Such estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses, and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The following are some, but not all, of such estimates: the determination of chargebacks, sales returns, rebates, billbacks, valuation of intangible and other assets acquired in business combinations, allowances for accounts receivable, accrued liabilities, initial and subsequent valuation of contingent consideration recognized in business combinations, stock-based compensation, valuation of inventory balances, the determination of useful lives for product rights and the assessment of expected cash flows used in evaluating goodwill and other long-lived assets for impairment. Actual results could differ from those estimates.</span></div>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassification</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The prior period balance related to liabilities for legal proceedings of $58.0 million, formerly included in accounts payable and accrued expenses as of December 31, 2021, has been reclassified to the balance sheet caption liabilities for legal proceedings to conform to the current period presentation in the consolidated balance sheets.</span></div>
CY2021Q4	us-gaap	Litigation Reserve LitigationReserve	58000000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	559355000	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	535075000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1056988000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1028180000	usd
CY2022Q2	amrx	Collaborative Arrangement Maximum Milestone Payment CollaborativeArrangementMaximumMilestonePayment	26500000	usd
	amrx	Collaborative Arrangement Maximum Milestone Payment CollaborativeArrangementMaximumMilestonePayment	26500000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-120808000	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	14532000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-122964000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	21238000	usd
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	150993000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	148996000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	150445000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	148507000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	150993000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	151986000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	150445000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	151606000	shares
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.80
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.10
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.82
CY2022Q2	amrx	Liabilities Under Tax Receivable Agreement Noncurrent LiabilitiesUnderTaxReceivableAgreementNoncurrent	206300000	usd
CY2021Q4	amrx	Liabilities Under Tax Receivable Agreement Noncurrent LiabilitiesUnderTaxReceivableAgreementNoncurrent	206300000	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.14
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.80
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.10
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.82
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.14
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7400000	usd
CY2022Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.032
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2600000	usd
CY2021Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.076
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3900000	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.016
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3000000	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.060
CY2019Q3	amrx	Estimated Pre Tax Loss Term EstimatedPreTaxLossTerm	P3Y
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	416600000	usd
	amrx	Percentage Of Tax Benefits Under Tax Receivable Agreement PercentageOfTaxBenefitsUnderTaxReceivableAgreement	0.85
CY2021Q4	amrx	Cash Discount Allowances Current CashDiscountAllowancesCurrent	23642000	usd
CY2022Q2	amrx	Allowance For Accounts Receivable Current AllowanceForAccountsReceivableCurrent	420963000	usd
CY2021Q4	amrx	Allowance For Accounts Receivable Current AllowanceForAccountsReceivableCurrent	529209000	usd
CY2022Q2	amrx	Liabilities Under Tax Receivable Agreement Noncurrent LiabilitiesUnderTaxReceivableAgreementNoncurrent	206300000	usd
CY2021Q4	amrx	Liabilities Under Tax Receivable Agreement Noncurrent LiabilitiesUnderTaxReceivableAgreementNoncurrent	206300000	usd
CY2022Q2	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	1109812000	usd
CY2021Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	1191792000	usd
CY2022Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1933000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1665000	usd
CY2022Q2	amrx	Contract Charge Backs And Sales Volume Allowances Current ContractChargeBacksAndSalesVolumeAllowancesCurrent	395748000	usd
CY2021Q4	amrx	Contract Charge Backs And Sales Volume Allowances Current ContractChargeBacksAndSalesVolumeAllowancesCurrent	503902000	usd
CY2022Q2	amrx	Cash Discount Allowances Current CashDiscountAllowancesCurrent	23282000	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	688849000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	662583000	usd
CY2022Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	220593000	usd
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	214508000	usd
CY2022Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	71784000	usd
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	47802000	usd
CY2022Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	240651000	usd
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	227079000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	533028000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	489389000	usd
CY2022Q2	us-gaap	Interest Rate Cash Flow Hedge Asset At Fair Value InterestRateCashFlowHedgeAssetAtFairValue	56221000	usd
CY2022Q2	amrx	Deferred Compensation Plan Liabilities Fair Value Disclosures DeferredCompensationPlanLiabilitiesFairValueDisclosures	10648000	usd
CY2022Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	14626000	usd
CY2021Q4	us-gaap	Interest Rate Cash Flow Hedge Liability At Fair Value InterestRateCashFlowHedgeLiabilityAtFairValue	11473000	usd
CY2021Q4	amrx	Deferred Compensation Plan Liabilities Fair Value Disclosures DeferredCompensationPlanLiabilitiesFairValueDisclosures	13883000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	5900000	usd
CY2022Q2	us-gaap	Aoci Loss Cash Flow Hedge Cumulative Gain Loss After Tax AociLossCashFlowHedgeCumulativeGainLossAfterTax	56200000	usd
CY2022Q2	amrx	Gain Loss Related To Litigation Settlement Net Of Imputed Interest GainLossRelatedToLitigationSettlementNetOfImputedInterest	-262800000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	593017000	usd
CY2020Q4	us-gaap	Goodwill Goodwill	522814000	usd
	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	7553000	usd
CY2021	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	70584000	usd
	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	3075000	usd
CY2021	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	0	usd
	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-2671000	usd
CY2021	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-381000	usd
CY2022Q2	us-gaap	Goodwill Goodwill	600974000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	593017000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1374671000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	575872000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	798799000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1256412000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	494915000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	761497000	usd
CY2022Q2	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	405425000	usd
CY2022Q2	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	405425000	usd
CY2021Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	405425000	usd
CY2021Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	405425000	usd
CY2022Q2	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	1780096000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	575872000	usd
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1204224000	usd
CY2021Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	1661837000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	494915000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1166922000	usd
	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	73800000	usd
CY2021Q2	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	73800000	usd
CY2022Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	41982000	usd
CY2021Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	43520000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	82901000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	85192000	usd
CY2022Q2	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	405400000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	88560000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	161146000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	158554000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	120845000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	72132000	usd
CY2022Q2	amrx	Finite Lived Intangible Assets Amortization Expense After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	197562000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	798799000	usd
CY2022Q2	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-251877000	usd
CY2021Q2	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	usd
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-249551000	usd
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	usd
CY2022Q2	us-gaap	Litigation Reserve Current LitigationReserveCurrent	275338000	usd
CY2021Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	58000000	usd
CY2022Q2	amrx	Liabilities For Legal Matters Imputed Interest LiabilitiesForLegalMattersImputedInterest	2082000	usd
CY2022Q2	amrx	Liabilities For Legal Matters Accrued Interest LiabilitiesForLegalMattersAccruedInterest	90000	usd
CY2021Q4	amrx	Liabilities For Legal Matters Accrued Interest LiabilitiesForLegalMattersAccruedInterest	0	usd
CY2022Q2	us-gaap	Litigation Reserve Noncurrent LitigationReserveNoncurrent	48008000	usd
CY2021Q4	us-gaap	Litigation Reserve Noncurrent LitigationReserveNoncurrent	0	usd
CY2022Q2	amrx	Litigation Settlement Initial Discount Amount LitigationSettlementInitialDiscountAmount	2200000	usd
	amrx	Gain Loss Related To Litigation Settlement Net Of Imputed Interest GainLossRelatedToLitigationSettlementNetOfImputedInterest	-262800000	usd
	us-gaap	Litigation Settlement Interest LitigationSettlementInterest	2200000	usd
CY2022Q2	us-gaap	Escrow Deposit EscrowDeposit	100000000	usd
CY2022Q2	amrx	Loss Contingency Pending Claims Including Third Parties Number LossContingencyPendingClaimsIncludingThirdPartiesNumber	915	case
CY2022Q2	amrx	Loss Contingency Number Of Cases LossContingencyNumberOfCases	119	case
CY2022Q2	amrx	Loss Contingency Number Of States With Cases LossContingencyNumberOfStatesWithCases	11	state
CY2022Q1	amrx	Loss Contingency New Lawsuit Filed Number LossContingencyNewLawsuitFiledNumber	2	lawsuit
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3	segment
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	559355000	usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	353724000	usd
CY2022Q2	us-gaap	Production Related Impairments Or Charges ProductionRelatedImpairmentsOrCharges	5112000	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	200519000	usd
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	98806000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	50748000	usd
CY2022Q2	us-gaap	Royalty Expense RoyaltyExpense	821000	usd
CY2022Q2	amrx	Business Combination Acquisition Related Costs Transaction Related And Integration Expense BusinessCombinationAcquisitionRelatedCostsTransactionRelatedAndIntegrationExpense	241000	usd
CY2022Q2	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-251877000	usd
CY2022Q2	us-gaap	Insurance Recoveries InsuranceRecoveries	1911000	usd
CY2022Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-270000	usd
CY2022Q2	amrx	Other Income Operating OtherIncomeOperating	1175000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-198618000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1056988000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	676786000	usd
	us-gaap	Production Related Impairments Or Charges ProductionRelatedImpairmentsOrCharges	5112000	usd
	us-gaap	Gross Profit GrossProfit	375090000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	197471000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	103546000	usd
	us-gaap	Royalty Expense RoyaltyExpense	1585000	usd
	amrx	Business Combination Acquisition Related Costs Transaction Related And Integration Expense BusinessCombinationAcquisitionRelatedCostsTransactionRelatedAndIntegrationExpense	675000	usd
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-249551000	usd
	us-gaap	Insurance Recoveries InsuranceRecoveries	1911000	usd
	us-gaap	Restructuring Charges RestructuringCharges	731000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-70000	usd
	amrx	Other Income Operating OtherIncomeOperating	1175000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-175313000	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	535075000	usd
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	322577000	usd
CY2021Q2	us-gaap	Gross Profit GrossProfit	212498000	usd
CY2021Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	86157000	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	52864000	usd
CY2021Q2	us-gaap	Asset Impairment Charges AssetImpairmentCharges	710000	usd
CY2021Q2	us-gaap	Royalty Expense RoyaltyExpense	1365000	usd
CY2021Q2	amrx	Business Combination Acquisition Related Costs Transaction Related And Integration Expense BusinessCombinationAcquisitionRelatedCostsTransactionRelatedAndIntegrationExpense	4283000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	67119000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1028180000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	624120000	usd
	us-gaap	Gross Profit GrossProfit	404060000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	176883000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	101046000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	710000	usd
	us-gaap	Royalty Expense RoyaltyExpense	4947000	usd
	amrx	Business Combination Acquisition Related Costs Transaction Related And Integration Expense BusinessCombinationAcquisitionRelatedCostsTransactionRelatedAndIntegrationExpense	7085000	usd
	us-gaap	Restructuring Charges RestructuringCharges	363000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	113026000	usd
CY2022Q2	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	0	usd
CY2021Q2	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	0	usd
	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	0	usd
	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	0	usd
CY2022Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	24904000	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	47861000	usd
CY2022Q2	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	1338000	usd
CY2021Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	1179000	usd
CY2022Q2	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	10654000	usd
CY2021Q4	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	9619000	usd
CY2022Q2	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	2900000	usd
	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	7300000	usd
CY2021Q2	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	16600000	usd
	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	25900000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	16717000	usd
CY2021	amrx	Changes In Reallocation Of Ownership Interests ChangesInReallocationOfOwnershipInterests	-226000	usd
	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	25807000	usd
	amrx	Changes In Reallocation Of Ownership Interests ChangesInReallocationOfOwnershipInterests	-112000	usd
CY2022Q2	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	1694000	usd
CY2021Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	1174000	usd
CY2022Q2	us-gaap	Prepaid Insurance PrepaidInsurance	7478000	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	7962000	usd
CY2022Q2	amrx	Prepaid Regulatory Fees Current PrepaidRegulatoryFeesCurrent	1265000	usd
CY2021Q4	amrx	Prepaid Regulatory Fees Current PrepaidRegulatoryFeesCurrent	3710000	usd
CY2022Q2	amrx	Income And Other Taxes Receivable IncomeAndOtherTaxesReceivable	11535000	usd
CY2021Q4	amrx	Income And Other Taxes Receivable IncomeAndOtherTaxesReceivable	8850000	usd
CY2022Q2	us-gaap	Prepaid Taxes PrepaidTaxes	15953000	usd
CY2021Q4	us-gaap	Prepaid Taxes PrepaidTaxes	16085000	usd
CY2022Q2	us-gaap	Loss Contingency Receivable LossContingencyReceivable	148500000	usd
CY2021Q4	us-gaap	Loss Contingency Receivable LossContingencyReceivable	33000000	usd
CY2022Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	17748000	usd
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	9770000	usd
CY2022Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	20895000	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	17309000	usd
CY2022Q2	amrx	Chargebacks Receivable Current ChargebacksReceivableCurrent	7136000	usd
CY2021Q4	amrx	Chargebacks Receivable Current ChargebacksReceivableCurrent	12358000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	232204000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	110218000	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	79836000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	20614000	usd
	amrx	Other Income Operating OtherIncomeOperating	1200000	usd
CY2022Q2	amrx	Other Income Operating OtherIncomeOperating	1200000	usd
CY2022Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	2669376000	usd
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	2730750000	usd
CY2022Q2	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	17009000	usd
CY2021Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	20083000	usd
CY2022Q2	us-gaap	Long Term Debt LongTermDebt	2652367000	usd
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	2710667000	usd
CY2022Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	29920000	usd
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	30614000	usd
CY2022Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2622447000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2680053000	usd
CY2021Q3	amrx	Number Of Facilities Damaged NumberOfFacilitiesDamaged	2	facility
CY2021	us-gaap	Unusual Or Infrequent Item Loss Gross UnusualOrInfrequentItemLossGross	10400000	usd
CY2022Q2	us-gaap	Insurance Recoveries InsuranceRecoveries	1900000	usd
	us-gaap	Insurance Recoveries InsuranceRecoveries	1900000	usd

Files In Submission

Name	View Source	Status
0001723128-22-000034-index-headers.html	Edgar Link	pending
0001723128-22-000034-index.html	Edgar Link	pending
0001723128-22-000034.txt	Edgar Link	pending
0001723128-22-000034-xbrl.zip	Edgar Link	pending
amrx-20220630.htm	Edgar Link	pending
amrx-20220630.xsd	Edgar Link	pending
amrx-2022063010xqexx101.htm	Edgar Link	pending
amrx-2022063010xqexx311.htm	Edgar Link	pending
amrx-2022063010xqexx312.htm	Edgar Link	pending
amrx-2022063010xqexx313.htm	Edgar Link	pending
amrx-2022063010xqexx321.htm	Edgar Link	pending
amrx-2022063010xqexx322.htm	Edgar Link	pending
amrx-2022063010xqexx323.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
amrx-20220630_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
amrx-20220630_pre.xml	Edgar Link	unprocessable
amrx-20220630_lab.xml	Edgar Link	unprocessable
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
amrx-20220630_cal.xml	Edgar Link	unprocessable
amrx-20220630_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AMRX
Amneal Pharmaceuticals, Inc. Stock $amrx

2022 Q2 Form 10-Q Financial Statement

#000172312822000034 Filed on August 08, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AMRX Amneal Pharmaceuticals, Inc. Stock $amrx

2022 Q2 Form 10-Q Financial Statement

#000172312822000034 Filed on August 08, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AMRX
Amneal Pharmaceuticals, Inc. Stock $amrx